Merck & Co., Inc. Today
Merck & Co., Inc.
- 52-week range
- $ 86.93
▼
$ 134.63
- Dividend yield
- 3.70%
- P/e ratio.
- 13.02
- Value is valuable
- $ 119.06
Big Pharma fell into close attention of regulatory organs and consumers as a mood in the industry. Thus, the market can be inexorable when companies even pass expectations or forecasts a little. This is so s Merck & Co. Inc. NYSE: MRKSince the shares lost more than 10% after they reported the results of profit in the fourth quarter of 2024.
While the company reported a solid dish per share for 11 cents, since revenue increased by 6.8% to $ 15.62 billion. The United States, surpassing the consensus estimates for $ 15.48 billion, it was the 2025 leadership that shocked the confidence of the investor. Merck Guined EPS from 8.88 to 9.03 US dollars against $ 9.13. Assessment of analysis and income from $ 64.1 billion to 65.6 billion dollars, which also did not reach consensus estimates at $ 67.07 billion.
The fall can be considered as the possibility of buying a medical sector for a giant. Here are 4 reasons not compiled to buy this fall in Merck Stock.
1) The lack of leadership was caused by a deliberate pause in deliveries to China
The entire deficit of the leadership of the upper and lower leadership may be associated with the intentional decision of Merck on the suspension of the supply of his Gardasil to China from February to mid -2025.
Merck & Co., Inc. MARKETRANK ™ shares Analysis
- General market ™
- 100th percentile
- Analyst rating
- Moderate purchase
- Breaking/disadvantage
- 35.6% growth
- Short level of interest
- Healthy
- The power of dividends
- Strong
- Environmental assessment
- -2.86
- Mood news
- 0.85
- Insider trade
- Acquisition of shares
- Professe Earnings growth
- 10.10%
See full analysis
Gardasil is a vaccine against human papilloma (HPV), which is used to prevent diseases and cancer caused by HPV. Gardasil sales in the 4th quarter fell by 17% to 1.55 billion dollars, which missed analysts at $ 1.61 billion. Throughout 2024, Gardasil brought sales for $ 8.6 billion. The USA, which has decreased by 3%by 3%.
The reason for the temporary stop of shipment is to give the market the opportunity to work out their inventory in China and allow the distributors to adjust the reserves on demand. This obviously indicates the problem of demand, but Merck insists that growth will resume in the second half of 2025. Gardasil dominates the vaccines against the HPV, but is still faced with competition GSK PLC NYSE: GSK Bivalent vaccine against HPV CERVARIX.
2) Merk medicine pipeline costs more than 50 billion dollars
In his conference conference in Q4, Merck General Director Rob Davis said that they have 20 potential new drivers for growing pipelines, almost all of which are opportunities for the growth of blockbusters. Some of them include their adult pneumococcal conjugate vaccines Winrevair and Capvaxive, currently launched in the United States. Merk has many promising methods of treatment in phase 3 development. In fact, Merck tripled the number of drugs in the development of 3rd stage 3 over the past three years. Davis said: “Based on significant progress, we see more than $ 50 billion potential for income from these programs.”
3) Merck Stock represents the value at these levels
After falling prices for 10% of the Merck shares, they are currently traded in the amount of only 11.45 -fold forward compared to the average in the 30.22X industry. Its traction 12-month (TTM) price ratio (p/e) at the level of 18.29 below 10-year-old median p/e 25.36. Its ratio of sale price (P/S) is 3.45 compared to the average in the industry 4.31. Its shares are paid 3.71% of the annual dividend profitability with a strong ratio of their own capital 0.79 and the credit rating A+ for the balance of the fortress, which leads to the TTM operational cash flow in the amount of $ 18.26 billion. Shares are traded by 35.3% of their maximum, 37.91% of their target price target price, as well as for three years.
4) MRK -the events are approaching the triple monthly level of support
Triple support consists of three overlapping levels of trend lines, bumpers or indicators. Singer terms tend to have higher prices.
The MRK CandleStick MRK’s monthly chart illustrates a sharp decrease from maximums. Promotions are approaching triple support for price levels. Three support levels converge at about $ 86.02 to 85.48 US dollars, followed by another double support at the level of $ 83.05 to 82.56 US dollars. The first level of triple support consists of expansion of Threndline lower tails (Purple), price support of $ 86.02 (green) and monthly fixed support of VWAP in 85.48 dollars (orange). The second double support level is support for $ 86.02 (green) and FIB 0.076 $ 0.076 (light green). Whole The range of support clusters is from 82.56 to 86.02 US dollars.Field
Current options strategies: Bull investors can consider the issue of use, protected from cash, at the levels of FIB rollback to buy DIP. In the case of the appointment of shares, then writing a coated call at the levels of increase FIB performs a wheel strategy for income in addition to its annual dividend yield by 3.71%.
Before considering Merck & Co., Inc., you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their customers to buy now before the wider market wins … and Merck & Co., Inc. There was no on the list.
While Merck & Co., Inc. Currently, it has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Want to know where to start (or finish) with AI shares? These 10 simple shares can help investors create long -term wealth, since artificial intelligence continues to grow into the future.
Get this free report